Imidazoylalkyl substituted with a six membered nitrogen containing
heterocyclic ring
    1.
    发明授权
    Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring 失效
    被六元含氮杂环取代的咪唑烷基

    公开(公告)号:US5807872A

    公开(公告)日:1998-09-15

    申请号:US244830

    申请日:1994-06-15

    IPC分类号: C07D401/06 A61K31/445

    CPC分类号: C07D401/06

    摘要: Disclosed is a compound of Formula 1.0: ##STR1## or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of Formula 1.0. Further disclosed is a method of treating allergy (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma)--i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypo motility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimers, Schizophrenia, and migraine) comprising administering an effective amount of a compound of Formula 1.0 to a patient in need of such treatment.

    摘要翻译: PCT No.PCT / US92 / 10698 Sec。 371日期:1994年6月15日 102(e)日期1994年6月15日PCT提交1992年12月16日PCT公布。 公开号WO93 / 12107 PCT 日期1993年6月24日公开是式1.0的化合物:其中1.0或其药学上可接受的盐或溶剂合物。 还公开了包含药学上可接受的载体和有效量的式1.0化合物的药物组合物。 进一步公开的是治疗过敏(例如哮喘),炎症,高血压,升高的眼内压(例如青光眼)的方法,降低眼内压的方法,睡眠障碍,超低运动性和酸性分泌的状态 胃肠道,中枢神经系统的低血压和多动症(例如,激动和抑郁)和其他CNS疾病(例如阿尔茨海默病,精神分裂症和偏头痛),包括向有需要的患者施用有效量的式1.0化合物 这样的治疗。

    Imidazoylalkyl substituted with a six membered nitrogen containing
nitrogen containing heterocyclic ring
    2.
    发明授权
    Imidazoylalkyl substituted with a six membered nitrogen containing nitrogen containing heterocyclic ring 失效
    用含六价氮的含氮杂环取代的咪唑烷基

    公开(公告)号:US5932596A

    公开(公告)日:1999-08-03

    申请号:US457352

    申请日:1995-06-01

    IPC分类号: C07D401/06 A61K31/445

    CPC分类号: C07D401/06

    摘要: Disclosed is a compound of Formula 1.0: ##STR1## or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of Formula 1.0.Further disclosed is a method of treating allergy (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma)--i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypo motility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimers, Schizophrenia, and migraine) comprising administering an effective amount of a compound of Formula 1.0 to a patient in need of such treatment.

    摘要翻译: 公开了式1.0的化合物或其药学上可接受的盐或溶剂化物。 还公开了包含药学上可接受的载体和有效量的式1.0化合物的药物组合物。 进一步公开的是治疗过敏(例如哮喘),炎症,高血压,升高的眼内压(例如青光眼)的方法,降低眼内压的方法,睡眠障碍,超低运动性和酸性分泌的状态 胃肠道,中枢神经系统的低血压和多动症(例如,激动和抑郁)和其他CNS疾病(例如阿尔茨海默病,精神分裂症和偏头痛),包括向有需要的患者施用有效量的式1.0化合物 这样的治疗。